Floatz logo

Therapeutic Asset Ratings

193 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Inno-206
Endometrial Cancer
AstraZenecaP3BB (66)
Olaparib
Endometrial Cancer
Qilu Pharmaceutical Co., Ltd.P4BB (64)
Palbociclib
Endometrial Cancer
University Medical Center GroningenP4BB (64)
FILGRASTIM
Endometrial Cancer
Mayo ClinicP3B (61)
Carboplatin
Endometrial Cancer
Qilu Pharmaceutical Co., Ltd.P3B (60)
Cyclophosphamide
Endometrial Cancer
Sutro Biopharma, Inc.P3B (60)
Docetaxel
Endometrial Cancer
Merck Sharp & Dohme LLCP3B (60)
Epirubicin
Endometrial Cancer
Sutro Biopharma, Inc.P3B (60)
Pembrolizumab
Endometrial Cancer
Eikon TherapeuticsP3B (60)
Rilvegostomig
Endometrial Cancer
AstraZenecaP3B (60)
LENVATINIB
Endometrial Cancer
University Medical Center GroningenP4B (59)
Eloxatin
Endometrial Cancer
Qilu Pharmaceutical Co., Ltd.P2B (59)
CIS-DIAMMINEDICHLOROPLATINUM II
Endometrial Cancer
Qilu Pharmaceutical Co., Ltd.P2B (58)
FLUOROURACILUM
Endometrial Cancer
Parabilis Medicines, Inc.P2B (58)
su011248
Endometrial Cancer
University Medical Center GroningenP4B (57)
Octreotide Pamoate
Endometrial Cancer
National Cancer Institute (NCI)P3B (57)
Calcium folinate pentahydrate
Endometrial Cancer
Parabilis Medicines, Inc.P2B (57)
FULVESTRANT
Endometrial Cancer
Terremoto Biosciences Inc.P2B (57)
Irinotecan
Endometrial Cancer
Whitehawk Therapeutics, Inc.P2B (57)
Letrozole
Endometrial Cancer
Avenzo Therapeutics, Inc.P2B (57)
Puxitatug Samrotecan
Endometrial Cancer
AstraZenecaP3B (56)
Sacituzumab Tirumotecan
Endometrial Cancer
Merck Sharp & Dohme LLCP3B (56)
Trastuzumab Deruxtecan
Endometrial Cancer
AstraZenecaP3B (56)
Abemaciclib
Endometrial Cancer
Avenzo Therapeutics, Inc.P2B (56)
TRASTUZUMAB
Endometrial Cancer
Fate TherapeuticsP2B (56)
Showing 1 to 25 of 193 assets
PreviousPage 1 of 8Next